

The Medical Letter®

on Drugs and Therapeutics

Volume 68

August 31, 2026

ISSUE No.

1762

IN THIS ISSUE

In Brief: *Rextovy* – Another OTC Naloxone Nasal Spray p 143

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 68 (Issue 1762)

August 31, 2026

Take CME Exam

IN BRIEF

Rextovy – Another OTC Naloxone Nasal Spray

The FDA has approved the over-the-counter (OTC) sale of *Rextovy* (Amphastar), a nasal spray formulation of the opioid antagonist naloxone, for emergency treatment of opioid overdose.¹ Other naloxone nasal sprays (*Narcan*, and generics; *RiVive*) are also available OTC (see Table 1).^{2,3}

Rextovy was approved in 2023 as a prescription product. It was approved for OTC sale based on data demonstrating that it is safe and effective for use as directed in the proposed labeling and that consumers can use it properly without the supervision of a healthcare professional.⁴

Table 1. OTC Naloxone Nasal Sprays

Product	Formulation ¹	Cost ²
<i>Narcan</i> (Emergent) generic	4 mg/0.1 mL	\$34.99 ³ 48.90
<i>Rextovy</i> (Amphastar)	4 mg/0.25 mL	45.00
<i>RiVive</i> (Harm Reduction)	3 mg/0.1 mL	36.00

1. The recommended initial dose is one spray in one nostril; additional doses can be administered in alternating nostrils every 2-3 minutes as needed until emergency medical personnel arrive.

2. Approximate WAC for one box containing 2 doses. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. August 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/drug-pricing-policy.

3. Cost for one box containing 2 doses at target.com.

Naloxone is the drug of choice for reversal of opioid overdose. According to the CDC, persons (and their close contacts) who take opioids illicitly, in high doses, or concurrently with benzodiazepines should carry naloxone.⁵ Every state in the US now has a naloxone access law; in most states, these laws grant both civil and criminal immunity to laypersons who administer the drug.⁶

Rextovy is available in packages containing two single-use nasal spray devices, each of which delivers 4 mg of naloxone. The recommended initial dose is one spray in one nostril; additional doses can be administered in alternating nostrils every 2-3 minutes as needed until emergency medical personnel arrive. ■

1. FDA News Release. FDA broadens access to over-the-counter naloxone nasal spray for opioid overdose. June 16, 2026. Available at: <https://bit.ly/43Nz0KB>. Accessed August 11, 2026.
2. In brief: Over-the-counter Narcan nasal spray. Med Lett Drugs Ther 2023; 65:72.
3. In brief: A new OTC naloxone nasal spray (RiVive). Med Lett Drugs Ther 2024; 66:47.
4. FDA. Prescription-to-nonprescription (Rx-to-OTC) switches. May 21, 2026. Available at: <https://bit.ly/43Tndu7>. Accessed August 11, 2026.
5. CDC. Lifesaving naloxone. June 11, 2025. Available at: <https://bit.ly/3QfTetm>. Accessed August 11, 2026.
6. Legislative Analysis and Public Policy Association. Overdose reversal agent access: summary of state laws. January 2025. Available at: <https://bit.ly/4fVXrul>. Accessed August 11, 2026.

PRESIDENT, EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **EDITOR IN CHIEF EMERITUS:** Mark Abramowicz, M.D.; **VICE PRESIDENT, ADMINISTRATION:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., B.C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Dartmouth Hitchcock Medical Center; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer. The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
The Medical Letter, Inc.
2 Madison Ave, Ste 211
Larchmont, NY 10538
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
1 year – \$179; \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints – \$45 per issue or article

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected: 

Copyright 2026. ISSN 1523-2859

The
Medical
Letter